Tan Fei, Thiele Carol J, Li Zhijie
Department of Neurology, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, P.R. China.
Cell and Molecular Biology Section, Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Oncol Lett. 2014 May;7(5):1333-1340. doi: 10.3892/ol.2014.1909. Epub 2014 Feb 24.
The collapsin response mediator proteins (CRMPs) were originally identified as mediators of semaphorin 3A signaling and neuronal differentiation. The CRMP family consists of five homologous cytosolic proteins, CRMP1-5. Altered expression levels of CRMPs have been observed in several malignant tumors, including lung, breast, colorectal, prostate, pancreatic and neuroendocrine lung cancer. The aim of the current study was to review the recent progress achieved in understanding the association between the different levels of CRMP expression in tumors and their involvement in pathological functions, such as tumor metastasis, disease progression, subtype differentiation and clinical outcome, to address the potential value of CRMPs as biomarkers for the diagnosis and prognosis of cancer patients.
塌陷反应介导蛋白（CRMPs）最初被鉴定为信号素3A信号传导和神经元分化的介质。CRMP家族由五种同源的胞质蛋白CRMP1 - 5组成。在几种恶性肿瘤中观察到CRMPs的表达水平发生改变，包括肺癌、乳腺癌、结直肠癌、前列腺癌、胰腺癌和神经内分泌肺癌。本研究的目的是回顾在理解肿瘤中不同水平的CRMP表达与其参与病理功能（如肿瘤转移、疾病进展、亚型分化和临床结果）之间的关联方面所取得的最新进展，以探讨CRMPs作为癌症患者诊断和预后生物标志物的潜在价值。
